{"id":"aminolevulinic-acid","rwe":[{"pmid":"41890773","year":"2026","title":"Safety and Efficacy of Aminolevulinic Acid Hydrochloride Topical Gel, 10%, with Red Light in the Treatment of Facial Cutaneous Squamous Cell Carcinoma In Situ.","finding":"","journal":"The Journal of clinical and aesthetic dermatology","studyType":"Clinical Study"},{"pmid":"41881187","year":"2026","title":"Metabolic engineering of microbial pathways for 5-aminolevulinic acid biosynthesis: Recent advances and biotechnological applications.","finding":"","journal":"Metabolic engineering","studyType":"Clinical Study"},{"pmid":"41873782","year":"2026","title":"Combined 5-aminolevulinic acid and ferric ammonium citrate treatment promotes hair follicle growth by activating dermal papilla cells.","finding":"","journal":"FEBS open bio","studyType":"Clinical Study"},{"pmid":"41872081","year":"2026","title":"Skin physiology during daylight photodynamic therapy with additional fractional laser therapy.","finding":"","journal":"European journal of dermatology : EJD","studyType":"Clinical Study"},{"pmid":"41867500","year":"2026","title":"Adhesive hydrogel delivering ALA prevents the malignant transformation of oral leukoplakia.","finding":"","journal":"Materials today. Bio","studyType":"Clinical Study"}],"_fda":{"id":"425c0da5-cec7-4a38-88ee-b230c0601f51","set_id":"4873911e-a5d7-47e3-9679-fa5c95999323","openfda":{"upc":["0359137231017"],"unii":["V35KBM8JGR"],"route":["ORAL"],"spl_id":["425c0da5-cec7-4a38-88ee-b230c0601f51"],"brand_name":["GLEOLAN"],"spl_set_id":["4873911e-a5d7-47e3-9679-fa5c95999323"],"package_ndc":["59137-231-01"],"product_ndc":["59137-231"],"generic_name":["AMINOLEVULINIC ACID HYDROCHLORIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["AMINOLEVULINIC ACID HYDROCHLORIDE"],"manufacturer_name":["Medexus Pharma, Inc."],"application_number":["NDA208630"],"is_original_packager":[true]},"version":"3","pregnancy":["8.1 Pregnancy Risk Summary There are no available human data on Gleolan in pregnant women to inform a drug associated risk of adverse developmental outcomes. In animal reproduction studies, no adverse developmental effects were observed with oral ALA HCl administration to pregnant rabbits during organogenesis at doses 3 times the maximum recommended human oral dose (see Data ) . The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Animal data ALA HCl was administered to rabbits at oral doses of 15, 50 and 150 mg/kg/day [approximately 0.1, 0.6, and 3 times the maximum human recommended dose (MHRD), respectively based on AUC comparisons] from gestation days 6-18. The no-observed-adverse-effect level (NOAEL) for maternal toxicity was 50 mg/kg/day and the NOAEL for embryo-fetal developmental toxicity was 150 mg/kg/day."],"overdosage":["10 OVERDOSAGE Overdosage has been associated with respiratory insufficiency and erythema. In the event of overdose, supportive measures should be provided as necessary, including protection from strong light sources."],"description":["11 DESCRIPTION 11.1 Chemical Properties Gleolan (aminolevulinic acid hydrochloride) is an optical imaging agent for oral solution. The 50-mL, clear vial contains 1,500 mg of lyophilized aminolevulinic acid hydrochloride powder (equivalent to 1,170 mg aminolevulinic acid). After reconstitution, the product has a concentration of 30 mg aminolevulinic acid hydrochloride per mL (equivalent to 23.4 mg aminolevulinic acid per mL). The chemical name is 5-amino-4-oxo-pentanoic acid hydrochloride. The chemical formula for aminolevulinic acid hydrochloride is C 5 H 10 ClNO 3 . Its molecular weight is 167.59 g/mol with the following structural formula: Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Gleolan (NDC 59137-231-01) is supplied as 1,500 mg of lyophilized aminolevulinic acid hydrochloride powder (equivalent to 1,170 mg aminolevulinic acid), for oral solution in a 50-mL clear, colorless, glass vial with a rubber stopper and an aluminum crimp seal. 16.2 Storage and Handling Store at 25 °C (77 °F); excursions permitted to 15-30 °C (59-86 °F)."],"geriatric_use":["8.5 Geriatric Use Of 527 subjects in clinical studies of Gleolan, 182 were 65 to < 75 years of age and 7 were ≥ 75 years of age. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. No dose adjustment is required in elderly patients."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of Gleolan in pediatric patients have not been established."],"effective_time":"20240503","clinical_studies":["14 CLINICAL STUDIES The efficacy of 20 mg / kg ALA HCl was evaluated in 3 clinical studies (Study 1-3) involving patients, ages 18 to 75 years old, who had a preoperative MRI compatible with high-grade glioma (WHO Grade III or IV) and were undergoing surgical resection. Study 1 was an open-label study of 33 patients with newly diagnosed high-grade glioma and Study 2 was an open-label study of 36 patients with recurrent high-grade glioma. In Studies 1 and 2, after initial debulking was carried out under white light, biopsies were obtained under fluorescent light from fluorescent and nonfluorescent sites. Presence of fluorescence (positive/negative) was compared to tumor status (true/false) using histopathology as the reference standard. True positives and false positives among fluorescent biopsies and true negatives and false negatives among nonfluorescent biopsies are provided in Table 1. Study 3 was a randomized, multicenter study in 415 patients with a preoperative diagnosis of high-grade glioma by MRI. Patients were randomized in 1:1 ratio to ALA fluorescence arm or to white light control arm. Biopsies were obtained from tumor-core, tumor-margin and regions just distant to the tumor margins. In 349 patients high grade glioma was confirmed by a blinded central read and histopathology. The remaining patients were diagnosed with metastatic disease, abscess, low-grade glioma or other conditions. In patients with confirmed high-grade glioma randomized to the ALA fluorescence arm, presence of fluorescence at a biopsy level was compared to tumor status using histopathology as the reference standard (Table 1). In 4 patients with low-grade glioma (WHO Grade I or II) who received ALA HCl, 9 out of 10 biopsies were false negative. The extent of resection among patients with confirmed high-grade glioma in the ALA fluorescence arm was compared to that among patient in the control arm, with the \"completeness\" of resection being determined by a central blinded read of early post-surgical MRI. Percentage of patients who had \"completeness\" of resection was 64% in the ALA arm and 38% in the control arm, with the difference of 26% [95% CI: (16%, 36%)]. Table 1. Presence of Fluorescence Compared to Histopathology (biopsy level) Study 1 (N=297) N is Number of total (fluorescent and non-fluorescent) biopsies Study 2 (N=370) Study 3 (N=479) Number of Fluorescent Biopsies 185 354 319 True Positive 178 342 312 False Positive 7 12 7 Number of Nonfluorescent Biopsies 112 16 160 True Negative 27 3 30 False Negative 85 13 130"],"pharmacodynamics":["12.2 Pharmacodynamics The effect of the timing of the Gleolan dosing on fluorescence intensity in brain tissue is unknown. The relationship between systemic ALA plasma concentrations at the time of visualization and fluorescence intensity in brain is also unknown. The dose of 20 mg / kg provided stronger ALA-induced fluorescence in glioma tissue by both visual and spectrophotometric assessment compared to lower doses tested. Cardiac Electrophysiology Administration of the approved recommended dose of Gleolan did not prolong the QT interval to any clinically relevant extent."],"pharmacokinetics":["12.3 Pharmacokinetics In 12 healthy subjects, the mean half-life of ALA following the recommended dose of Gleolan solution was 0.9 ± 1.2 hours (mean ± std dev) with a range of 0.8 to 1.3 hours. Maximum concentrations of the PpIX metabolite (T max for PpIX) occurred with a median of 4 hours and a range of 1.2 to 7.8 hours. The elimination half-life of PpIX was 3.6 ± 1.8 hours (mean ± std dev) with a range of 1.2 to 7.8 hours. Absorption In 12 healthy subjects, the absolute bioavailability of ALA following the recommended dose of Gleolan solution was 100.0% ± 1.1 with a range of 78.5% to 131.2%. Maximum ALA plasma concentrations were reached with a median of 0.8 hour (range 0.5 – 1.0 hour). Distribution In in vitro experiments using ALA concentrations up to approximately 25% of the maximal concentration that occurs in plasma following the recommended dose of Gleolan solution, the mean protein binding of ALA was 12%. Elimination Metabolism Exogenous ALA is metabolized to PpIX, but the fraction of administered ALA that is metabolized to PpIX is unknown. The average plasma AUC of PpIX is less than 6% of that of ALA. Excretion In 12 healthy subjects, excretion of parent ALA in urine in the 12 hours following administration of the recommended dose of Gleolan solution was 34 ± 8% (mean ± std dev) with a range of 27% to 57%. Specific Populations The effect of renal or hepatic impairment on the pharmacokinetics of ALA following Gleolan administration is unknown. Drug Interaction Studies In vitro studies suggest that phenytoin and other anti-convulsants may decrease cellular PpIX accumulation following Gleolan dosing. ALA is not an inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A."],"adverse_reactions":["6 ADVERSE REACTIONS Adverse reactions occurring in >1% of patients in the week following surgery were pyrexia, hypotension, nausea, and vomiting. ( 6.1 ) Adverse reactions occurring in < 1% of patients in the first 6 weeks after surgery were: chills, photosensitivity reaction, solar dermatitis, hypotension, abnormal liver function test, and diarrhea. ( 6.1 ) Neurologic events related to the surgical procedure occurred in 29% of patients and included: aphasia, hemiparesis, hemianopia, headache, seizure, hemiplegia, monoparesis, hypoesthesia, and brain edema. ( 6.1 ) Elevated liver enzymes occurred in clinical studies. There were no cases of liver failure. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact NXDC toll-free at (844) 517-5252 and adverseevents@nxdevcorp.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of Gleolan is supported by data from 5 open label clinical studies, which included 527 patients with glioma who received ALA HCl. Adverse reactions that occurred in > 1% of patients in the week following surgery were pyrexia, hypotension, nausea, and vomiting. Adverse reactions occurring in the first 6 weeks after surgery in < 1% of patients were: chills, photosensitivity reaction, solar dermatitis, hypotension, abnormal liver function test, and diarrhea. One patient experienced respiratory failure due to drug overdose [see Overdosage (10) ] . Neurologic Events Nervous system disorders occurred in 29% of patients within the first week after surgery. Events occurring in > 1% of patients included aphasia (8%), hemiparesis (7.8%), hemianopsia (3.2%), headache (2.7%), seizure (1.9%), hemiplegia (1.9%), monoparesis (1.3%) and hypoesthesia (1.1%). Brain edema occurred in < 1 % of patients in the first 6 weeks after surgery. In a randomized clinical trial (Study 3), the numbers of serious neurologic adverse events in the post operative period were higher in patients randomized to ALA fluorescence arm compared to the control arm. An imbalance was notable for the adverse events aphasia, ataxia, convulsion and hemianopsia, and is likely related to the higher amount of brain resection performed in the ALA arm. At longer follow up periods, the numbers between the two arms appeared similar [see Clinical Trials (14) ] . Elevated Liver Enzymes Worsening of ≥ 2 Common Toxicity Criteria (CTC) grades in alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT) occurred in (15.8% and 11.6%, respectively) within the first week after surgery. Absolute levels ranged from 2 times to greater than 10 times the upper limit of normal (ULN) for each parameter. At 6 weeks, ALT remained elevated in 2.9% of patients (range 2 to greater than 5 × ULN), and GGT was elevated in 7.5% of patients (range 2 to greater than 10 × ULN). No cases of liver failure occurred. 6.2 Post Marketing Experience The following adverse reactions are among those that have been identified during post-approval use of Gleolan outside of the United States. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Immune Disorders : anaphylactic shock, angioedema, drug eruption, urticaria, erythema. Metabolism and Nutrition Disorders : metabolic acidosis."],"contraindications":["4 CONTRAINDICATIONS Hypersensitivity to the aminolevulinic acid (ALA) or porphyrins. [see Warnings and Precautions (5.3) ] Acute or chronic types of porphyria, due to potential ineffectiveness of the drug in these patients. Hypersensitivity to aminolevulinic acid (ALA) or porphyrins. ( 4 , 5.3 , 6.2 ) Acute or chronic types of porphyria. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Phototoxic Drugs Patients exposed to a photosensitizing agent may experience a phototoxic skin reaction (severe sunburn). Due to the risk of possible phototoxic reactions, avoid administering phototoxic drugs such as St. John's wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones and tetracyclines, and topical preparations containing ALA for 24 hours before and after administration of Gleolan."],"mechanism_of_action":["12.1 Mechanism of Action ALA occurs endogenously as a metabolite that is formed in the mitochondria from succinyl-CoA and glycine. Exogenous administration of ALA leads to accumulation of the ALA metabolite PpIX in tumor cells. The reason for the accumulation of PpIX in neoplastic brain tissue is not known. During glioma surgery, Gleolan is used with an operating microscope adapted with a blue emitting light source (power density 40-80 mW/cm 2 ) and filters for excitation light of wavelength 375 to 440 nm, and observation at wavelengths of 620 to 710 nm. This allows tumor tissue to be visualized as red fluorescence. Tissue lacking sufficient PpIX concentrations appears blue."],"storage_and_handling":["16.2 Storage and Handling Store at 25 °C (77 °F); excursions permitted to 15-30 °C (59-86 °F)."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action ALA occurs endogenously as a metabolite that is formed in the mitochondria from succinyl-CoA and glycine. Exogenous administration of ALA leads to accumulation of the ALA metabolite PpIX in tumor cells. The reason for the accumulation of PpIX in neoplastic brain tissue is not known. During glioma surgery, Gleolan is used with an operating microscope adapted with a blue emitting light source (power density 40-80 mW/cm 2 ) and filters for excitation light of wavelength 375 to 440 nm, and observation at wavelengths of 620 to 710 nm. This allows tumor tissue to be visualized as red fluorescence. Tissue lacking sufficient PpIX concentrations appears blue. 12.2 Pharmacodynamics The effect of the timing of the Gleolan dosing on fluorescence intensity in brain tissue is unknown. The relationship between systemic ALA plasma concentrations at the time of visualization and fluorescence intensity in brain is also unknown. The dose of 20 mg / kg provided stronger ALA-induced fluorescence in glioma tissue by both visual and spectrophotometric assessment compared to lower doses tested. Cardiac Electrophysiology Administration of the approved recommended dose of Gleolan did not prolong the QT interval to any clinically relevant extent. 12.3 Pharmacokinetics In 12 healthy subjects, the mean half-life of ALA following the recommended dose of Gleolan solution was 0.9 ± 1.2 hours (mean ± std dev) with a range of 0.8 to 1.3 hours. Maximum concentrations of the PpIX metabolite (T max for PpIX) occurred with a median of 4 hours and a range of 1.2 to 7.8 hours. The elimination half-life of PpIX was 3.6 ± 1.8 hours (mean ± std dev) with a range of 1.2 to 7.8 hours. Absorption In 12 healthy subjects, the absolute bioavailability of ALA following the recommended dose of Gleolan solution was 100.0% ± 1.1 with a range of 78.5% to 131.2%. Maximum ALA plasma concentrations were reached with a median of 0.8 hour (range 0.5 – 1.0 hour). Distribution In in vitro experiments using ALA concentrations up to approximately 25% of the maximal concentration that occurs in plasma following the recommended dose of Gleolan solution, the mean protein binding of ALA was 12%. Elimination Metabolism Exogenous ALA is metabolized to PpIX, but the fraction of administered ALA that is metabolized to PpIX is unknown. The average plasma AUC of PpIX is less than 6% of that of ALA. Excretion In 12 healthy subjects, excretion of parent ALA in urine in the 12 hours following administration of the recommended dose of Gleolan solution was 34 ± 8% (mean ± std dev) with a range of 27% to 57%. Specific Populations The effect of renal or hepatic impairment on the pharmacokinetics of ALA following Gleolan administration is unknown. Drug Interaction Studies In vitro studies suggest that phenytoin and other anti-convulsants may decrease cellular PpIX accumulation following Gleolan dosing. ALA is not an inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A."],"indications_and_usage":["1 INDICATIONS AND USAGE Gleolan is indicated in patients with glioma [suspected World Health Organization (WHO) Grades III or IV on preoperative imaging] as an adjunct for the visualization of malignant tissue during surgery. Gleolan is an optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Phototoxic reactions: Do not administer phototoxic drugs (St. John's wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones and tetracyclines), and topical preparations containing ALA for 24 hours during the perioperative period. Reduce exposure to sunlight or room lights for 48 hours after oral administration of Gleolan. ( 5.1 , 7 ) Risk of misinterpretation: Non-fluorescing tissue in the surgical field does not rule out the presence of tumor. ( 5.2 , 14 ) 5.1 Risk of Phototoxic Reaction Due to the risk of phototoxic reactions, do not administer phototoxic drugs (St. John's wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones and tetracyclines), and topical preparations containing ALA for 24 hours during the perioperative period [see Drug Interactions (7) ] . Reduce exposure to sunlight or room lights for 48 hours after administration of Gleolan. 5.2 Risk of Misinterpretation Errors may occur with the use of Gleolan for intraoperative visualization of malignant glioma, including false negatives and false positives. Non-fluorescing tissue in the surgical field does not rule out the presence of tumor in patients with glioma [see Clinical Studies (14) ] . Fluorescence may be seen in areas of inflammation or metastases from other tumor types. 5.3 Hypersensitivity Reactions Hypersensitivity reactions, including serious hypersensitivity reactions have occurred; these reactions include anaphylactic shock, swelling, and urticaria [see Contraindications (4) , Adverse Reactions (6.2) ] . Always have cardiopulmonary resuscitation personnel and equipment readily available and monitor all patients for hypersensitivity reactions."],"clinical_studies_table":["
Table 1. Presence of Fluorescence Compared to Histopathology (biopsy level)
Study 1 (N=297)N is Number of total (fluorescent and non-fluorescent) biopsies
Study 2 (N=370)
Study 3 (N=479)
Number of Fluorescent Biopsies
185
354
319
True Positive
178
342
312
False Positive
7
12
7
Number of Nonfluorescent Biopsies
112
16
160
True Negative
27
3
30
False Negative
85
13
130
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis No carcinogenicity studies have been conducted with Gleolan. Mutagenesis ALA HCl was not mutagenic in the Ames assay, HPRT-V79 mammalian cell mutagenicity test, the peripheral human lymphocyte chromosomal aberration assay and the in vivo mouse micronucleus test when studies were performed in the dark or under subdued lighting. Impairment of Fertility No fertility studies have been conducted with Gleolan."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise patients that they may experience elevated liver enzymes (ALT and GGT) within the first week after surgery. This elevation may persist after 6 weeks. Advise patients to reduce exposure to sunlight or room lights for 48 hours after administration of Gleolan due to risk of phototoxic reactions."],"spl_unclassified_section":["Manufactured for: NX Development Corp. Lexington, KY 40503 Distributed by: Medexus Pharma, Inc. Chicago, IL 60606 Product of Germany APX1182"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION For oral use only ( 2.1 ) Recommended reconstituted oral dose of Gleolan is 20 mg/kg. ( 2.1 ) Administer Gleolan to patient orally 3 hours (range 2 to 4 hours) before anesthesia. ( 2.1 ) See Full Prescribing Information for reconstitution information. ( 2.2 ) Use appropriate visualization techniques with appropriate surgical microscopes and light source filters. ( 2.4 ) 2.1 Recommended Dose For oral use only The recommended oral dose of reconstituted Gleolan is 20 mg / kg body weight. More than 1 vial may be required. 2.2 Reconstitution of Gleolan Gleolan powder must be reconstituted prior to administration by a healthcare provider according to the following instructions: Determine the total number of vials needed to achieve the intended dose for the patient according to the equation below (rounded up to the nearest whole vial): # of vials = Patient Body Weight (kg) 75 kg / vial Completely remove the white cap and aluminum crimp seal from each vial. Remove and retain the rubber stopper from the vial. Using an appropriate volumetric measuring device (e.g., flask, graduated cylinder, dosing syringe), measure 50 mL of drinking water and add to each vial containing 1,500 mg of Gleolan. Gently swirl the vial to completely dissolve the powder. The resulting reconstituted solution (30 mg of Gleolan per mL) is clear and colorless to slightly yellowish. If required, replace the stopper and store reconstituted solution for up to 24 hours at room temperature prior to administration. 2.3 Gleolan Administration Gleolan is for ORAL USE ONLY. The reconstituted Gleolan solution is administered according to the following steps: Calculate the administration volume, in mL, to achieve the intended dose according to the following equation: Administration Volume (mL) = Patient Body Weight (kg) * 20 mg/kg 30 mg/mL Transfer the entire contents of the prepared vial(s) into an appropriate dosing container (e.g., oral medicine bottle); ensure the entire contents of the vials are transferred. After transfer, discard the empty vial(s). Using a disposable volumetric syringe, remove the administration volume of reconstituted Gleolan solution from the dosing container and transfer to a separate oral dosing container. Discard unneeded volume of Gleolan solution. Administer orally 3 hours (range 2 to 4 hours) prior to induction of anesthesia. 2.4 Imaging Instructions Gleolan should be used with a standard surgical operating microscope adapted with a blue light emitting light source (power density 40-80 mW/cm 2 ) and ancillary excitation and emission filters to visualize fluorescence excitation in the wavelength of 375 to 440 nm and for observation from 620 to 710 nm. Filters transmit porphyrin fluorescence as red-violet, as well as a fraction of backscattered blue excitation light necessary for distinguishing nonfluorescing tissue. Gleolan should only be used by neurosurgeons who have completed a training program on use of fluorescence in surgery. Training is provided by the distributor."],"spl_product_data_elements":["GLEOLAN AMINOLEVULINIC ACID HYDROCHLORIDE AMINOLEVULINIC ACID HYDROCHLORIDE AMINOLEVULINIC ACID CLEAR TO SLIGHTLY YELLOWISH"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS For oral solution: 1,500 mg aminolevulinic acid hydrochloride (ALA HCl) lyophilized powder, equivalent to 1,170 mg aminolevulinic acid (ALA) , in a 50 mL single-dose clear, colorless, glass vial with rubber stopper. After reconstitution with 50 mL drinking water, the solution contains 30 mg per mL of aminolevulinic acid hydrochloride (equivalent to 23.4 mg per mL of aminolevulinic acid) and is clear and colorless to slightly yellowish in color. For oral solution: 1,500 mg aminolevulinic acid hydrochloride lyophilized powder, equivalent to 1,170 mg aminolevulinic acid per vial. The reconstituted aminolevulinic acid hydrochloride solution contains 30 mg per mL and is clear and colorless to slightly yellowish in color. ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no available human data on Gleolan in pregnant women to inform a drug associated risk of adverse developmental outcomes. In animal reproduction studies, no adverse developmental effects were observed with oral ALA HCl administration to pregnant rabbits during organogenesis at doses 3 times the maximum recommended human oral dose (see Data ) . The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Animal data ALA HCl was administered to rabbits at oral doses of 15, 50 and 150 mg/kg/day [approximately 0.1, 0.6, and 3 times the maximum human recommended dose (MHRD), respectively based on AUC comparisons] from gestation days 6-18. The no-observed-adverse-effect level (NOAEL) for maternal toxicity was 50 mg/kg/day and the NOAEL for embryo-fetal developmental toxicity was 150 mg/kg/day. 8.2 Lactation Risk summary There are no data on the presence of ALA HCl in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Gleolan and any potential adverse effects on the breastfed infant from Gleolan or from the underlying maternal condition. Clinical Considerations To decrease exposure to Gleolan to the breastfed infant, advise a lactating woman to pump and discard breast milk after the administration of Gleolan for 24 hours (i.e., 5 to 6 half-lives). 8.4 Pediatric Use The safety and effectiveness of Gleolan in pediatric patients have not been established. 8.5 Geriatric Use Of 527 subjects in clinical studies of Gleolan, 182 were 65 to < 75 years of age and 7 were ≥ 75 years of age. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. No dose adjustment is required in elderly patients. 8.6 Patients with Renal Impairment Because approximately one third of the ALA dose is excreted in urine as parent drug, ALA clearance may be reduced in patients with renal impairment; it is not known if dose adjustment is needed [see Clinical Pharmacology (12.3) ] . 8.7 Patients with Hepatic Impairment The contribution of the liver to the elimination of ALA following Gleolan dosing is unknown. ALA clearance may be reduced in patients with hepatic impairment; it is not known if dose adjustment is needed [see Clinical Pharmacology (12.3) ] ."],"dosage_and_administration_table":["
# of vials=
Patient Body Weight (kg)
75kg / vial
","
Administration Volume (mL) =
Patient Body Weight (kg)* 20mg/kg
30mg/mL
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 1,500 mg Vial Carton NDC 59137-231-01 Rx only Gleolan ® (aminolevulinic acid hydrochloride) for oral solution 1,500 mg Reconstitute Prior To Use. For Oral Use Only SINGLE-DOSE VIAL. Discard Unused Portion One Vial MEDEXUS PHARMA PRINCIPAL DISPLAY PANEL - 1,500 mg Vial Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis No carcinogenicity studies have been conducted with Gleolan. Mutagenesis ALA HCl was not mutagenic in the Ames assay, HPRT-V79 mammalian cell mutagenicity test, the peripheral human lymphocyte chromosomal aberration assay and the in vivo mouse micronucleus test when studies were performed in the dark or under subdued lighting. Impairment of Fertility No fertility studies have been conducted with Gleolan."]},"tags":[{"label":"Optical Imaging Agent","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"L01XD04","category":"atc"},{"label":"Oral","category":"route"},{"label":"Topical","category":"route"},{"label":"Gel","category":"form"},{"label":"Powder","category":"form"},{"label":"Active","category":"status"},{"label":"Actinic keratosis","category":"indication"},{"label":"Fluorescent stain","category":"indication"},{"label":"Non-Hyperkeratotic Actinic Keratoses","category":"indication"},{"label":"Sun Pharm Inds Inc","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Dermatologic Agents","category":"pharmacology"},{"label":"Photosensitizing Agents","category":"pharmacology"},{"label":"Radiation-Sensitizing Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":283.798,"date":"","count":51,"signal":"Application site erythema","source":"DrugCentral FAERS","actionTaken":"Reported 51 times (LLR=284)"},{"llr":243.568,"date":"","count":44,"signal":"Application site pain","source":"DrugCentral FAERS","actionTaken":"Reported 44 times (LLR=244)"},{"llr":133.015,"date":"","count":104,"signal":"Off label use","source":"DrugCentral FAERS","actionTaken":"Reported 104 times (LLR=133)"},{"llr":127.386,"date":"","count":59,"signal":"Erythema","source":"DrugCentral FAERS","actionTaken":"Reported 59 times (LLR=127)"},{"llr":116.6,"date":"","count":18,"signal":"Application site swelling","source":"DrugCentral FAERS","actionTaken":"Reported 18 times (LLR=117)"},{"llr":110.716,"date":"","count":12,"signal":"Application site pustules","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=111)"}],"commonSideEffects":[{"effect":"Elevated Liver Enzymes","drugRate":"15.8%","severity":"common","_validated":true},{"effect":"Anaphylactic shock","drugRate":"reported","severity":"serious"},{"effect":"Angioedema","drugRate":"reported","severity":"serious"},{"effect":"Drug eruption","drugRate":"reported","severity":"mild"},{"effect":"Urticaria","drugRate":"reported","severity":"mild"},{"effect":"Erythema","drugRate":"reported","severity":"mild"},{"effect":"Metabolic acidosis","drugRate":"reported","severity":"serious"}],"contraindications":["Photosensitivity"],"specialPopulations":{"Lactation":"There are no data on the presence of ALA HCl in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mothers clinical need for Gleolan and any potential adverse effects on the breastfed infant from Gleolan or from the underlying maternal condition.","Pregnancy":"There are no available human data on Gleolan in pregnant women to inform drug associated risk of adverse developmental outcomes. In animal reproduction studies, no adverse developmental effects were observed with oral ALA HCl administration to pregnant rabbits during organogenesis at doses times the maximum recommended human oral dose (see Data).The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of major birth defects and miscarriage of 2% to 4% and 15% to 20%, respectively.","Geriatric use":"Of the 384 subjects exposed to AMELUZ in randomized, multicenter clinical trials, 83% (318/384) of the subjects were 65 years old and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.","Paediatric use":"The safety and effectiveness of Gleolan in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"Sun Pharma","patents":[{"applNo":"N020965","source":"FDA Orange Book","status":"Active","expires":"Jan 12, 2038","useCode":"U-3163","territory":"US","drugProduct":false,"patentNumber":"11690914","drugSubstance":false},{"applNo":"N020965","source":"FDA Orange Book","status":"Active","expires":"Jan 12, 2038","useCode":"U-3163","territory":"US","drugProduct":false,"patentNumber":"11077192","drugSubstance":false},{"applNo":"N020965","source":"FDA Orange Book","status":"Active","expires":"Oct 13, 2036","useCode":"U-804","territory":"US","drugProduct":false,"patentNumber":"12290700","drugSubstance":false},{"applNo":"N020965","source":"FDA Orange Book","status":"Active","expires":"Oct 13, 2036","useCode":"U-804","territory":"US","drugProduct":false,"patentNumber":"11697028","drugSubstance":false},{"applNo":"N020965","source":"FDA Orange Book","status":"Active","expires":"Jan 17, 2037","useCode":"U-804","territory":"US","drugProduct":false,"patentNumber":"11446512","drugSubstance":false},{"applNo":"N020965","source":"FDA Orange Book","status":"Active","expires":"Oct 13, 2036","useCode":"U-804","territory":"US","drugProduct":false,"patentNumber":"11179574","drugSubstance":false},{"applNo":"N020965","source":"FDA Orange Book","status":"Active","expires":"Jan 12, 2038","useCode":"U-3163","territory":"US","drugProduct":false,"patentNumber":"12296011","drugSubstance":false},{"applNo":"N020965","source":"FDA Orange Book","status":"Active","expires":"Jan 12, 2038","useCode":"U-3163","territory":"US","drugProduct":false,"patentNumber":"10357567","drugSubstance":false},{"applNo":"N020965","source":"FDA Orange Book","status":"Active","expires":"Jan 12, 2038","useCode":"U-3163","territory":"US","drugProduct":false,"patentNumber":"11571478","drugSubstance":false},{"applNo":"N020965","source":"FDA Orange Book","status":"Active","expires":"Jan 12, 2038","useCode":"U-3163","territory":"US","drugProduct":false,"patentNumber":"11135293","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=AMINOLEVULINIC ACID","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:48:42.953759+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:48:42.953656+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:48:48.171789+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMINOLEVULINIC ACID","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:48:48.495384+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:48:41.154322+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:48:41.154348+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: DNA inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:48:50.417611+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200582/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:48:50.080241+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA208630","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:48:41.154351+00:00"}},"allNames":"levulan","offLabel":[],"synonyms":["ameluz","aminolevulinic acid","5-amino-4-oxopentanoic acid","aladerm","alasens","5-aminolevulinic acid","5-aminolevulinic acid hydrochloride","Gliolan","aminolevulinic acid hydrochloride","5-aminolevulinic acid HCl","aminolevulinic acid HCl"],"timeline":[{"date":"1999-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from DUSA to Sun Pharm Inds Inc"},{"date":"1999-12-03","type":"positive","source":"DrugCentral","milestone":"FDA approval (Dusa)"},{"date":"2016-05-10","type":"positive","source":"FDA Orange Book","milestone":"Ameluz approved — 10%"},{"date":"2017-06-06","type":"positive","source":"FDA Orange Book","milestone":"Gleolan approved — 1.5GM/VIAL"}],"aiSummary":"Levulan (Aminolevulinic Acid) is a small molecule optical imaging agent originally developed by DUSA and currently owned by Sun Pharm Inds Inc. It was FDA-approved in 1999 for the treatment of actinic keratosis, fluorescent stain, and non-hyperkeratotic actinic keratoses. Levulan works by accumulating in abnormal skin cells, allowing for visualization and subsequent treatment. It has a half-life of 0.83 hours and 60% bioavailability. Levulan is a patented product with no generic manufacturers.","brandName":"Levulan","ecosystem":[{"indication":"Actinic keratosis","otherDrugs":[{"name":"diclofenac","slug":"diclofenac","company":""},{"name":"fluorouracil","slug":"fluorouracil","company":"Spectrum Pharms"},{"name":"imiquimod","slug":"imiquimod","company":"Medicis"},{"name":"ingenol mebutate","slug":"ingenol-mebutate","company":"Leo Pharma As"}],"globalPrevalence":null},{"indication":"Fluorescent stain","otherDrugs":[],"globalPrevalence":null},{"indication":"Non-Hyperkeratotic Actinic Keratoses","otherDrugs":[{"name":"methyl aminolevulinate","slug":"methyl-aminolevulinate","company":"Galderma Labs Lp"}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","moaClass":"Fluorescence Contrast Activity","modality":"Small Molecule","drugClass":"Optical Imaging Agent","explanation":"Photoactivation following topical application of AMELUZ occurs when aminolevulinic acid (prodrug) is metabolized to protoporphyrin IX (PpIX), photoactive compound which accumulates in the skin. When exposed to red light of suitable wavelength and energy, PpIX is activated resulting in an excited state of porphyrin molecules. In the presence of oxygen, reactive oxygen species are formed which causes damage to cellular components, and eventually destroys the cells. AMELUZ photodynamic therapy of AK lesions utilizes photoactivation of topically applied AMELUZ resulting from BF-RhodoLED or RhodoLED XL illumination, which provides red light of narrow spectrum and light dose of approximately 37 J/cm2.","oneSentence":"Levulan accumulates in abnormal skin cells, allowing for visualization and treatment.","technicalDetail":"Levulan is a prodrug that is converted to protoporphyrin IX (PpIX) in the skin, which accumulates in abnormal cells and is excited by blue light, producing a fluorescent signal that can be visualized."},"commercial":{"launchDate":"1999","_launchSource":"DrugCentral (FDA 1999-12-03, DUSA)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/166","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AMINOLEVULINIC%20ACID","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMINOLEVULINIC ACID","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:41:36.114132","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:48:53.845075+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"porfimer","drugSlug":"porfimer","fdaApproval":"1995-12-27","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"methyl aminolevulinate","drugSlug":"methyl-aminolevulinate","fdaApproval":"2004-07-27","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"aminolevulinic acid","indications":{"approved":[{"name":"Actinic keratosis","source":"DrugCentral","snomedId":201101007,"regulator":"FDA","eligibility":"Patients with actinic keratoses of mild-to-moderate severity on the face and scalp."},{"name":"Fluorescent stain","source":"DrugCentral","snomedId":35352008,"regulator":"FDA"},{"name":"Non-Hyperkeratotic Actinic Keratoses","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Sun Pharm Inds Inc","drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"porfimer","brandName":"porfimer","genericName":"porfimer","approvalYear":"1995","relationship":"same-class"},{"drugId":"methyl-aminolevulinate","brandName":"methyl aminolevulinate","genericName":"methyl aminolevulinate","approvalYear":"2004","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06876038","phase":"PHASE2","title":"Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions","status":"NOT_YET_RECRUITING","sponsor":"University of Massachusetts, Boston","startDate":"2026-09","conditions":["Oral Cancer","Oral Cavity Cancer","Oral Leukoplakia","Oral Lichen Planus","Oral Squamous Cell Carcinoma"],"enrollment":65,"completionDate":"2028-12"},{"nctId":"NCT07225621","phase":"PHASE2","title":"Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Alpheus Medical, Inc.","startDate":"2026-01-28","conditions":["Glioblastoma","GBM"],"enrollment":103,"completionDate":"2028-12"},{"nctId":"NCT07241585","phase":"NA","title":"Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT)","status":"NOT_YET_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2026-05-01","conditions":["Nonmelanoma Skin Cancer","Basal Cell Carcinoma","Squamous Cell Carcinoma"],"enrollment":54,"completionDate":"2027-08"},{"nctId":"NCT06417281","phase":"PHASE3","title":"Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid（5-ALA）","status":"COMPLETED","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","startDate":"2024-06-19","conditions":["5-aminolevulinic Acid","Malignant Glioma of Brain"],"enrollment":86,"completionDate":"2025-08-19"},{"nctId":"NCT07144345","phase":"PHASE3","title":"Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2025-11-19","conditions":["Actinic Keratosis"],"enrollment":160,"completionDate":"2027-04"},{"nctId":"NCT06665724","phase":"PHASE1","title":"Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)","status":"COMPLETED","sponsor":"Universität Münster","startDate":"2025-01-27","conditions":["Anaplastic Astrocytoma (AA)","Anaplastic Oligodendroglioma (AO)","Glioblastoma (GBM)"],"enrollment":16,"completionDate":"2026-02-09"},{"nctId":"NCT07038278","phase":"EARLY_PHASE1","title":"5-AminoLevulinic Acid Aided Resection Margins in Sarcoma","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-04-01","conditions":["Soft Tissue Sarcoma (STS)"],"enrollment":20,"completionDate":"2028-11-01"},{"nctId":"NCT07076472","phase":"EARLY_PHASE1","title":"Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-08-14","conditions":["Progressive Glioblastoma","Recurrent Glioblastoma"],"enrollment":8,"completionDate":"2026-12-31"},{"nctId":"NCT07144852","phase":"PHASE3","title":"Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2025-11-29","conditions":["Actinic Keratosis"],"enrollment":260,"completionDate":"2027-04"},{"nctId":"NCT05923060","phase":"PHASE2","title":"Imaging Techniques to Monitor Photosensitizer and sO2 Levels During Photodynamic Therapy of Actinic Keratoses","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2024-08-25","conditions":["Actinic Keratoses"],"enrollment":14,"completionDate":"2025-10-31"},{"nctId":"NCT07420543","phase":"","title":"Clinical Significance of Liquid Biopsy in Brain Tumor Patients: a 5-ALA Guided Approach","status":"RECRUITING","sponsor":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","startDate":"2017-01-18","conditions":["Brain Tumors and/or Solid Tumors Including","Glioblastoma","Glioblastoma (GBM)","Glioblastoma - Category"],"enrollment":30,"completionDate":"2027-05"},{"nctId":"NCT05662202","phase":"PHASE3","title":"Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biofrontera Inc.","startDate":"2022-12-12","conditions":["Actinic Keratoses"],"enrollment":172,"completionDate":"2026-06"},{"nctId":"NCT06307548","phase":"PHASE1,PHASE2","title":"Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer","status":"SUSPENDED","sponsor":"Roswell Park Cancer Institute","startDate":"2024-07-30","conditions":["Locally Advanced Colorectal Carcinoma","Recurrent Colorectal Carcinoma","Stage III Colorectal Cancer"],"enrollment":21,"completionDate":"2027-06-01"},{"nctId":"NCT07201376","phase":"","title":"Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2025-11-14","conditions":["Non-Melanoma Skin Cancer (NMSC)","Benign Skin Growth"],"enrollment":125,"completionDate":"2027-11"},{"nctId":"NCT03048240","phase":"NA","title":"INtraoperative photoDYnamic Therapy of GliOblastoma","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2017-05-05","conditions":["Glioblastoma"],"enrollment":10,"completionDate":"2021-04-28"},{"nctId":"NCT06777511","phase":"","title":"Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients","status":"NOT_YET_RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2026-03-01","conditions":["Amputation","Osseointegration"],"enrollment":10,"completionDate":"2027-03-28"},{"nctId":"NCT07381972","phase":"PHASE3","title":"Photodynamic Therapy Associated With Sonodynamic Therapy for the Treatment of Nodular Basal Cell Carcinoma","status":"RECRUITING","sponsor":"University of Sao Paulo","startDate":"2025-11-24","conditions":["Nodular Basal Cell Carcinoma of Skin"],"enrollment":142,"completionDate":"2026-12"},{"nctId":"NCT06623201","phase":"PHASE1","title":"Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas","status":"RECRUITING","sponsor":"Nathalie Zeitouni","startDate":"2024-10-07","conditions":["Basal Cell Carcinoma (BCC)"],"enrollment":20,"completionDate":"2026-12-01"},{"nctId":"NCT04923516","phase":"","title":"Prevalence of Acute Hepatic Porphyria","status":"COMPLETED","sponsor":"Association pour la Recherche en Medecine Interne","startDate":"2021-08-23","conditions":["Acute Hepatic Porphyria"],"enrollment":150,"completionDate":"2023-12-29"},{"nctId":"NCT07366892","phase":"","title":"Leica Microsystems Sponsored PMCF Study to Collect and Confirm Clinical Data on the Performance of the GLOW400 Device When Used in Accordance With Its Intended Use","status":"NOT_YET_RECRUITING","sponsor":"Leica Microsystems (Schweiz) AG","startDate":"2026-02-01","conditions":["Suspected Grade III and IV Gliomas Requiring Surgical Intervention","Neurosurgical Procedure","Glioma","Glioblastoma (GBM)"],"enrollment":37,"completionDate":"2027-05-31"},{"nctId":"NCT06907485","phase":"PHASE2","title":"A Multicenter Study to Assess the Feasibility of 5-Aminolevulinic Acid (5-ALA) in Pediatric Brain Tumor Patients","status":"NOT_YET_RECRUITING","sponsor":"Costas Hadjipanayis","startDate":"2026-08","conditions":["Pediatric Brain Tumor"],"enrollment":20,"completionDate":"2028-08"},{"nctId":"NCT01561157","phase":"","title":"Longitudinal Study of the Porphyrias","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2010-11-01","conditions":["Acute Porphyrias","Cutaneous Porphyrias"],"enrollment":1500,"completionDate":"2030-06-30"},{"nctId":"NCT03573401","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biofrontera Inc.","startDate":"2018-09-25","conditions":["Superficial Basal Cell Carcinoma"],"enrollment":187,"completionDate":"2029-02"},{"nctId":"NCT07053852","phase":"PHASE1","title":"Activation of Ameluz With BBL HEROic for the Treatment of Actinic Keratoses and Photodamage","status":"COMPLETED","sponsor":"Sherrif Ibrahim","startDate":"2025-06-27","conditions":["Actinic Keratoses","Photodamage"],"enrollment":10,"completionDate":"2025-12-29"},{"nctId":"NCT05962541","phase":"PHASE4","title":"Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)","status":"RECRUITING","sponsor":"University of Roma La Sapienza","startDate":"2025-12-22","conditions":["Non-muscle-invasive Bladder Cancer","Non-Muscle Invasive Bladder Urothelial Carcinoma","High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma"],"enrollment":327,"completionDate":"2031-12"},{"nctId":"NCT07306247","phase":"NA","title":"Multicenter Prospective Non-randomized Controlled Study of ALA-PDT for LSIL With HPV16/18 Infection","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01","conditions":["HPV-16/18","Photodynamic Therapy (PDT)","LSIL, Low Grade Squamous Intraepithelial Lesion"],"enrollment":225,"completionDate":"2027-12"},{"nctId":"NCT05080764","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biofrontera Inc.","startDate":"2021-12-10","conditions":["Acne Vulgaris"],"enrollment":126,"completionDate":"2026-01"},{"nctId":"NCT07290959","phase":"NA","title":"Indoor Daylight Photodynamic Therapy is an Effective, First-line Treatment for AK, But Its Feasibility is Limited by the Time Required for the Illumination (2 Hours). Our Objective Was to Evaluate the Efficacy of Idl-PDT With an Illumination Time of 1 Hour Versus 2 Hours in the Treatment of Scalp AK","status":"COMPLETED","sponsor":"San Salvatore Hospital of L'Aquila","startDate":"2025-01-02","conditions":["Actinic Keratosis (AK)"],"enrollment":55,"completionDate":"2025-07-15"},{"nctId":"NCT02660645","phase":"","title":"Blue Light Cystoscopy With Cysview® Registry","status":"RECRUITING","sponsor":"Photocure","startDate":"2014-04","conditions":["Bladder Cancer"],"enrollment":4400,"completionDate":"2028-12"},{"nctId":"NCT07286903","phase":"","title":"Fluorescence Enhanced Stereotactic Surgery (FESS)","status":"RECRUITING","sponsor":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","startDate":"2024-07-01","conditions":["High Grade Glioma","High Grade Glioma (III or IV)"],"enrollment":20,"completionDate":"2026-12"},{"nctId":"NCT04738162","phase":"PHASE2","title":"Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Brain Tumors","status":"COMPLETED","sponsor":"Universität Münster","startDate":"2020-09-25","conditions":["Brain Tumor, Pediatric"],"enrollment":78,"completionDate":"2025-11-24"},{"nctId":"NCT04391062","phase":"PHASE2","title":"Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2021-09-28","conditions":["Glioblastoma"],"enrollment":14,"completionDate":"2024-03-25"},{"nctId":"NCT05020912","phase":"PHASE2","title":"Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2021-12-13","conditions":["Basal Cell Carcinoma"],"enrollment":28,"completionDate":"2027-12"},{"nctId":"NCT07075328","phase":"PHASE1,PHASE2","title":"A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma","status":"RECRUITING","sponsor":"Otsuka Medical Devices Co., Ltd. Japan","startDate":"2024-04-01","conditions":["Adult T-Cell Leukemia/Lymphoma (ATLL)"],"enrollment":49,"completionDate":"2028-08-31"},{"nctId":"NCT04223570","phase":"","title":"Portable Measurement of Protoporphyrin IX in the Skin","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2022-12-01","conditions":["Photodynamic Therapy","Protoporphyrin IX"],"enrollment":219,"completionDate":"2025-05-20"},{"nctId":"NCT07164053","phase":"","title":"Evaluation of Image Quality and Safety of the MyVeo Surgical Visualization Headset During Standard Neurosurgical and Reconstructive Procedures Using Compatible Microscopes.","status":"NOT_YET_RECRUITING","sponsor":"Leica Microsystems (Schweiz) AG","startDate":"2025-12-25","conditions":["High-Grade Glioma (WHO III-IV)","Cerebral Vascular Conditions Requiring Surgical Intervention","Conditions Requiring Plastic and Reconstructive Surgery"],"enrollment":32,"completionDate":"2027-06-30"},{"nctId":"NCT06525571","phase":"PHASE3","title":"Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-12-20","conditions":["Bladder Cancer"],"enrollment":200,"completionDate":"2028-01-04"},{"nctId":"NCT07111182","phase":"NA","title":"Intraoperative Fluorescence-Guided Aspirate Tissue Monitoring of 5-ALA During Brain Tumor Surgery","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-10-27","conditions":["Brain Neoplasms"],"enrollment":8,"completionDate":"2027-12-30"},{"nctId":"NCT04381806","phase":"PHASE1","title":"Phase I Study in Advanced Malignancies With 5-ALA","status":"SUSPENDED","sponsor":"Fox Chase Cancer Center","startDate":"2020-07-30","conditions":["Solid Tumor"],"enrollment":130,"completionDate":"2027-02-01"},{"nctId":"NCT06027619","phase":"PHASE2","title":"Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2023-10-02","conditions":["Actinic Keratosis"],"enrollment":30,"completionDate":"2024-07-08"},{"nctId":"NCT05804370","phase":"PHASE3","title":"Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)","status":"RECRUITING","sponsor":"NX Development Corp","startDate":"2024-05-30","conditions":["Ovarian Cancer"],"enrollment":170,"completionDate":"2027-05"},{"nctId":"NCT04400539","phase":"PHASE2","title":"The IMmunotherapy Pleural 5-ALA PDT","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2022-05-09","conditions":["Mesotheliomas Pleural","Malignant Pleural Mesothelioma"],"enrollment":20,"completionDate":"2026-05-09"},{"nctId":"NCT01811121","phase":"PHASE3","title":"MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2013-02","conditions":["Glioblastoma"],"enrollment":170,"completionDate":"2019-08"},{"nctId":"NCT02191488","phase":"PHASE1","title":"ALA-induced PpIX Fluorescence During Brain Tumor Resection","status":"ACTIVE_NOT_RECRUITING","sponsor":"David W. Roberts","startDate":"2014-07","conditions":["Brain Tumors"],"enrollment":540,"completionDate":"2026-12-31"},{"nctId":"NCT05736406","phase":"PHASE1,PHASE2","title":"A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma","status":"RECRUITING","sponsor":"Hemerion Therapeutics","startDate":"2024-02-20","conditions":["Primary Glioblastoma"],"enrollment":12,"completionDate":"2026-07"},{"nctId":"NCT04815083","phase":"PHASE3","title":"Fluorescence Imaging of Carcinoma During Breast Conserving Surgery","status":"TERMINATED","sponsor":"SBI ALApharma Canada, Inc.","startDate":"2021-04-27","conditions":["Breast Neoplasm Female","Breast Cancer"],"enrollment":57,"completionDate":"2024-12-20"},{"nctId":"NCT06455189","phase":"PHASE1","title":"Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas","status":"NOT_YET_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-12","conditions":["Glioblastoma","Brain Tumor"],"enrollment":114,"completionDate":"2029-12-31"},{"nctId":"NCT02691923","phase":"PHASE2","title":"Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker","status":"RECRUITING","sponsor":"David W. Roberts","startDate":"2016-03","conditions":["Brain Cancer"],"enrollment":30,"completionDate":"2026-12"},{"nctId":"NCT02373371","phase":"PHASE3","title":"Actinic Keratoses Treatment With Metvix® in Combination With Light","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2015-03-25","conditions":["Actinic Keratoses"],"enrollment":26,"completionDate":"2018-06-01"},{"nctId":"NCT05101798","phase":"PHASE2","title":"The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial","status":"TERMINATED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2021-09-14","conditions":["Neoplasm","Skull Base Neoplasm"],"enrollment":7,"completionDate":"2022-12-25"},{"nctId":"NCT05104099","phase":"PHASE2","title":"Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia","status":"COMPLETED","sponsor":"Institut de Cancérologie de Lorraine","startDate":"2021-11-29","conditions":["Vulvar Intraepithelial Neoplasia","Vulvar High Grade Squamous Intraepithelial Lesion","Differentiated Vulvar Intraepithelial Neoplasia"],"enrollment":17,"completionDate":"2025-05-25"},{"nctId":"NCT04780009","phase":"","title":"Loupe-Based Intraoperative Fluorescence Imaging","status":"RECRUITING","sponsor":"Guoqiang Yu","startDate":"2017-11-17","conditions":["Glioblastoma Multiforme","Anaplastic Astrocytoma"],"enrollment":30,"completionDate":"2026-06"},{"nctId":"NCT07027670","phase":"PHASE2","title":"Treatment With 5-AminoLEvuliNic Acid Before Cardiac Surgery","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-02-01","conditions":["Cardiac Surgical Procedures","Coronary Artery Bypass","Aortic Valve Disease","Mitral Valve Disease"],"enrollment":48,"completionDate":"2022-06-30"},{"nctId":"NCT05362409","phase":"PHASE1","title":"Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma","status":"COMPLETED","sponsor":"Alpheus Medical, Inc.","startDate":"2022-06-29","conditions":["High Grade Glioma"],"enrollment":22,"completionDate":"2025-02-03"},{"nctId":"NCT05474573","phase":"NA","title":"Concurrent Fluorescence and Sonographically Guided Eradication of Contrast-enhancing Gliomas and Metastases","status":"RECRUITING","sponsor":"Sklifosovsky Institute of Emergency Care","startDate":"2022-09-01","conditions":["Glioma, Malignant","Metastases to Brain"],"enrollment":52,"completionDate":"2027-08-31"},{"nctId":"NCT05475522","phase":"NA","title":"Intraoperative Sonographically Versus Fluorescence-guided Resection of Contrast-enhancing Gliomas and Brain Metastases","status":"SUSPENDED","sponsor":"Sklifosovsky Institute of Emergency Care","startDate":"2022-09-01","conditions":["Gliomas, Malignant","Metastases to Brain"],"enrollment":134,"completionDate":"2027-08-31"},{"nctId":"NCT03897491","phase":"PHASE2","title":"PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"photonamic GmbH & Co. KG","startDate":"2021-09-03","conditions":["Glioblastoma"],"enrollment":20,"completionDate":"2026-03"},{"nctId":"NCT06160492","phase":"PHASE3","title":"Phase III Clinical Trial Evaluating the Resection Efficacy of 5-Aminolevulinic Acid Hydrochloride (5-ALA HCl) Fluorescence-Guided Microsurgery Versus Conventional White Light Microsurgery in Patients With Malignant Glioma (WHO Grade 3/4)","status":"RECRUITING","sponsor":"Lee's Pharmaceutical Limited","startDate":"2025-04-14","conditions":["5-aminolevulinic Acid","Fluorescence-guided Resection"],"enrollment":144,"completionDate":"2026-03"},{"nctId":"NCT06052033","phase":"NA","title":"Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2023-09-11","conditions":["HPV-Related Cervical Carcinoma","Low-Grade Squamous Intraepithelial Lesions","HPV Infection","Photodynamic Therapy"],"enrollment":40,"completionDate":"2025-06-30"},{"nctId":"NCT04429308","phase":"PHASE2","title":"PDT vs Peels for Treatment of Actinic Keratoses","status":"NOT_YET_RECRUITING","sponsor":"Northwestern University","startDate":"2025-08","conditions":["Actinic Keratoses"],"enrollment":60,"completionDate":"2026-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Gel, Powder","formulations":[{"form":"GEL","route":"TOPICAL","productName":"AMELUZ"},{"form":"POWDER, FOR SOLUTION","route":"ORAL","productName":"GLEOLAN"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000176068","MMSL":"228491","NDDF":"009074","UNII":"88755TAZ87","VUID":"4025779","CHEBI":"CHEBI:17549","VANDF":"4023632","RXNORM":"1806646","UMLSCUI":"C0002563","chemblId":"CHEMBL1200582","ChEMBL_ID":"CHEMBL601","KEGG_DRUG":"D02908","DRUGBANK_ID":"DB00855","PDB_CHEM_ID":"FVT","PUBCHEM_CID":"137","SNOMEDCT_US":"259496005","IUPHAR_LIGAND_ID":"4784","SECONDARY_CAS_RN":"5451-09-2","MESH_DESCRIPTOR_UI":"D000622","MESH_SUPPLEMENTAL_RECORD_UI":"C000614854"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1999-","companyName":"Dusa","relationship":"Original Developer"},{"period":"present","companyName":"Sun Pharm Inds Inc","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.83 hours","clearance":"1.88 mL/min/kg","bioavailability":"60%","fractionUnbound":"0.88%","volumeOfDistribution":"0.12 L/kg"},"publicationCount":8397,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"L01XD04","allCodes":["L01XD04"]},"biosimilarFilings":[],"originalDeveloper":"Dusa","recentPublications":[{"date":"2026 Feb","pmid":"41890773","title":"Safety and Efficacy of Aminolevulinic Acid Hydrochloride Topical Gel, 10%, with Red Light in the Treatment of Facial Cutaneous Squamous Cell Carcinoma In Situ.","journal":"The Journal of clinical and aesthetic dermatology"},{"date":"2026 Mar 23","pmid":"41881187","title":"Metabolic engineering of microbial pathways for 5-aminolevulinic acid biosynthesis: Recent advances and biotechnological applications.","journal":"Metabolic engineering"},{"date":"2026 Mar 24","pmid":"41873782","title":"Combined 5-aminolevulinic acid and ferric ammonium citrate treatment promotes hair follicle growth by activating dermal papilla cells.","journal":"FEBS open bio"},{"date":"2026 Feb 1","pmid":"41872081","title":"Skin physiology during daylight photodynamic therapy with additional fractional laser therapy.","journal":"European journal of dermatology : EJD"},{"date":"2026 Apr","pmid":"41867500","title":"Adhesive hydrogel delivering ALA prevents the malignant transformation of oral leukoplakia.","journal":"Materials today. Bio"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Sun Pharm Inds Inc","companyId":"sun-pharma","modality":"Small molecule","firstApprovalDate":"1999","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:48:53.845075+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}